Nothing Special   »   [go: up one dir, main page]

BRPI0409911A - método para liberar uma molécula em uma célula, e, complexo carreador - Google Patents

método para liberar uma molécula em uma célula, e, complexo carreador

Info

Publication number
BRPI0409911A
BRPI0409911A BRPI0409911-7A BRPI0409911A BRPI0409911A BR PI0409911 A BRPI0409911 A BR PI0409911A BR PI0409911 A BRPI0409911 A BR PI0409911A BR PI0409911 A BRPI0409911 A BR PI0409911A
Authority
BR
Brazil
Prior art keywords
cell
molecule
release
carrier
carrier complex
Prior art date
Application number
BRPI0409911-7A
Other languages
English (en)
Inventor
Hazel H Szeto
Kesheng Zhao
Alex V Birk
D Robertson Hugh
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Publication of BRPI0409911A publication Critical patent/BRPI0409911A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

"MéTODO PARA LIBERAR UMA MOLéCULA EM UMA CéLULA, E, COMPLEXO CARREADOR". A invenção refere-se aos complexos carreadores e aos métodos para liberar moléculas em células. Os complexos carreadores compreendem uma molécula e um peptídeo catiónico aromático de acordo com a invenção. Em uma modalidade, o método para liberar uma molécula em uma célula compreende contatar a célula com um complexo carreador. Em outra modalidade, o método para liberar uma molécula em uma célula compreende contatar a célula com um peptídeo catiónico aromático.
BRPI0409911-7A 2003-05-01 2004-05-03 método para liberar uma molécula em uma célula, e, complexo carreador BRPI0409911A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46751603P 2003-05-01 2003-05-01
PCT/US2004/013772 WO2005001023A2 (en) 2003-05-01 2004-05-03 Method and carrier complexes for delivering molecules to cells

Publications (1)

Publication Number Publication Date
BRPI0409911A true BRPI0409911A (pt) 2006-04-25

Family

ID=33551404

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409911-7A BRPI0409911A (pt) 2003-05-01 2004-05-03 método para liberar uma molécula em uma célula, e, complexo carreador

Country Status (18)

Country Link
US (6) US7704954B2 (pt)
EP (7) EP2604287B1 (pt)
JP (6) JP4879020B2 (pt)
KR (1) KR101161823B1 (pt)
CN (2) CN100506841C (pt)
AU (1) AU2004252419B2 (pt)
BR (1) BRPI0409911A (pt)
CA (1) CA2524258C (pt)
DK (4) DK2604286T3 (pt)
ES (3) ES2520816T3 (pt)
HK (6) HK1089450A1 (pt)
MX (1) MXPA05011773A (pt)
NZ (1) NZ543410A (pt)
PL (2) PL2604286T3 (pt)
PT (2) PT2604285E (pt)
SI (1) SI2604285T1 (pt)
WO (1) WO2005001023A2 (pt)
ZA (1) ZA200509229B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030062788A (ko) * 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 ｍｐｈ1-ｂｔｍ 및 이것을포함하는 생명공학제품
DK2656854T3 (en) 2003-02-04 2015-07-06 Cornell Res Foundation Inc Applications of an aromatic-cationic peptide
KR101161823B1 (ko) 2003-05-01 2012-07-03 코넬 리서치 화운데이션,인크. 세포로 분자를 전달하는 방법 및 이것을 위한 캐리어 복합체
US7550439B2 (en) 2004-01-23 2009-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US7534819B2 (en) * 2005-06-10 2009-05-19 University Of Washington Compositions and methods for intracellular delivery of biotinylated cargo
CA2947341C (en) 2005-09-16 2019-03-05 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
KR20080084937A (ko) * 2005-11-04 2008-09-22 포휴먼텍(주) 융합 폴리펩타이드를 세포로 전달하는 방법
JP2009544688A (ja) * 2006-07-24 2009-12-17 フォーヒューマンテック カンパニー リミテッド 虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法
WO2008047243A2 (en) * 2006-08-29 2008-04-24 Forhumantech. Co., Ltd. Pharmaceutical composition for suppression of apoptosis and method for delivering the same
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
EP2712620A1 (en) 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
DK2262520T3 (en) 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
ES2666458T3 (es) * 2008-09-22 2018-05-04 Aileron Therapeutics, Inc. Macrociclos peptidomiméticos
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
US20100331265A1 (en) 2009-03-20 2010-12-30 Tompkins Ronald G Methods for the prevention and treatment of burn injuries and secondary complications
US20110039766A1 (en) * 2009-08-12 2011-02-17 Szeto Hazel H Methods for preventing or treating metabolic syndrome
CN105056206A (zh) * 2009-08-24 2015-11-18 康肽德生物医药技术有限公司 用于预防或治疗眼科病症的方法和组合物
WO2011044044A1 (en) 2009-10-05 2011-04-14 Cornell University Methods for the prevention or treatment of heart failure
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP3130599A1 (en) * 2010-05-03 2017-02-15 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN102010461B (zh) * 2010-10-11 2014-02-12 华南理工大学 一种alpha螺旋状阳离子多肽分子及其制法和应用
GB201018125D0 (en) * 2010-10-26 2010-12-08 Marealis As Peptide
CN107219358A (zh) * 2011-03-24 2017-09-29 康奈尔大学 芳香族阳离子肽及其用途
AU2012271691A1 (en) * 2011-06-14 2014-01-16 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
JP6025311B2 (ja) 2011-08-01 2016-11-16 キヤノン株式会社 眼科診断支援装置および方法
AU2012315586B2 (en) 2011-09-29 2017-07-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
JP6346092B2 (ja) * 2011-10-17 2018-06-20 コーネル ユニヴァーシティー 芳香族カチオン性ペプチドおよびその使用
WO2013059525A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
EP3009141A1 (en) * 2011-12-09 2016-04-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
CA2870200A1 (en) * 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
JP2015529655A (ja) 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
WO2014174517A1 (en) 2013-04-25 2014-10-30 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
EP3114136A4 (en) * 2014-03-03 2017-11-01 Stealth BioTherapeutics Corp Pharmaceutically relevant aromatic-cationic peptides
WO2015183995A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
EP3502132A1 (en) * 2014-05-28 2019-06-26 Stealth BioTherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
PL3160984T3 (pl) 2014-06-25 2021-10-25 Flamma S.P.A. Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylol- fenyloalaninoamidu
JP2017523957A (ja) * 2014-06-30 2017-08-24 フラマ ソシエタ ペル アチオニＦｌａｍｍａ Ｓ．Ｐ．Ａ． Ｄ−アルギニル−２，６−ジメチル−ｌ−チロシル−ｌ−リシル−ｌ−フェニルアラニンアミドの製造方法
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US20160228491A1 (en) * 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
WO2016209261A1 (en) * 2015-06-26 2016-12-29 Stealth Biotherapeutics Corp Therapeutic compositions including gramicidin s peptidyl conjugates or imidazole-substituted fatty acids, variants thereof, and uses thereof
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
JP7465494B2 (ja) 2015-10-21 2024-04-11 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン ナノ粒子での微小空洞及び虫歯の処置及び検出
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
US20200032214A1 (en) 2016-11-16 2020-01-30 Luca Science Inc. Method for producing myocardial stem cell used for treatment and/or prevention of cardiac arrest
EP4039250A1 (en) * 2016-12-28 2022-08-10 Chugai Seiyaku Kabushiki Kaisha Self-emulsifying drug formulation for improving membrane permeability of compound
CN107230021B (zh) * 2017-06-08 2020-05-26 桂林理工大学 筛选供水管网泄漏区域的方法
AU2019293857A1 (en) * 2018-06-29 2020-12-10 Glykos Finland Oy Conjugates
EP4081192A2 (en) 2019-12-27 2022-11-02 LUCA Science Inc. Isolated mitochondria with smaller size and lipid membrane-based vesicles encapsulating isolated mitochondria
WO2021216499A1 (en) * 2020-04-23 2021-10-28 North Carolina State University Cell-penetrating peptide-microrna conjugates for intracellular cell delivery
US11389431B2 (en) * 2020-09-09 2022-07-19 Social Profit Network Methods and compositions for delivery of biotin to mitochondria

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55500053A (pt) * 1978-01-16 1980-01-31
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
NL9001639A (nl) 1990-07-19 1992-02-17 Amc Amsterdam Pt-houdende verbinding, werkwijze voor de bereiding ervan, alsmede toepassing van dergelijke verbindingen.
US5714327A (en) 1990-07-19 1998-02-03 Kreatech Diagnostics Platinum-containing compounds, methods for their preparation and applications thereof
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
EP0747092B1 (en) 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2314267A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
DE60042338D1 (de) 1999-10-04 2009-07-16 Univ New Jersey Med TAR RNA bindende Peptide
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
GB0005703D0 (en) * 2000-03-09 2000-05-03 Alpharma As Compounds
AU2001277908A1 (en) 2000-07-18 2002-01-30 Cornell Research Foundation Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
GB0026924D0 (en) * 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
AU2002306500C1 (en) * 2001-02-16 2006-09-28 Cellgate, Inc. Transporters comprising spaced arginine moieties
DE10121982B4 (de) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
DK2656854T3 (en) * 2003-02-04 2015-07-06 Cornell Res Foundation Inc Applications of an aromatic-cationic peptide
KR101161823B1 (ko) 2003-05-01 2012-07-03 코넬 리서치 화운데이션,인크. 세포로 분자를 전달하는 방법 및 이것을 위한 캐리어 복합체
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
US7550439B2 (en) 2004-01-23 2009-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CA2947341C (en) 2005-09-16 2019-03-05 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
US20070259377A1 (en) 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
EP2712620A1 (en) 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
DK2262520T3 (en) 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
EP3814680A4 (en) 2018-06-29 2022-05-04 RealD Spark, LLC PRIVACY DISPLAY OPTICAL STACK

Also Published As

Publication number Publication date
HK1089450A1 (en) 2006-12-01
KR101161823B1 (ko) 2012-07-03
HK1186407A1 (en) 2014-03-14
US10584182B2 (en) 2020-03-10
EP2604621A1 (en) 2013-06-19
CA2524258C (en) 2012-08-07
ES2520815T3 (es) 2014-11-11
US20220372172A1 (en) 2022-11-24
US8148322B2 (en) 2012-04-03
US7704954B2 (en) 2010-04-27
US9315586B2 (en) 2016-04-19
MXPA05011773A (es) 2006-02-17
PT2604286E (pt) 2014-11-28
HK1231424A1 (zh) 2017-12-22
JP2011168603A (ja) 2011-09-01
JP2020105184A (ja) 2020-07-09
AU2004252419B2 (en) 2010-02-18
PL2604286T3 (pl) 2015-03-31
EP2604287A2 (en) 2013-06-19
CN100506841C (zh) 2009-07-01
EP2604287A3 (en) 2014-04-16
JP2018158951A (ja) 2018-10-11
EP2604285B1 (en) 2014-08-27
DK1625149T3 (en) 2016-05-30
EP3381515A1 (en) 2018-10-03
CA2524258A1 (en) 2005-01-06
WO2005001023A3 (en) 2005-04-28
SI2604285T1 (sl) 2014-12-31
EP3167935A1 (en) 2017-05-17
EP1625149B1 (en) 2016-02-17
US20050158373A1 (en) 2005-07-21
WO2005001023A2 (en) 2005-01-06
JP2014221846A (ja) 2014-11-27
US20200299415A1 (en) 2020-09-24
EP2604287B1 (en) 2016-12-07
EP3167935B1 (en) 2018-07-18
JP6698756B2 (ja) 2020-05-27
DK2604285T3 (en) 2014-12-01
CN1780851A (zh) 2006-05-31
EP2604286B1 (en) 2014-08-27
ZA200509229B (en) 2007-03-28
JP5650040B2 (ja) 2015-01-07
KR20060008950A (ko) 2006-01-27
US11845807B2 (en) 2023-12-19
US20130085259A1 (en) 2013-04-04
PT2604285E (pt) 2014-11-12
ES2694574T3 (es) 2018-12-21
US11180574B2 (en) 2021-11-23
US20170035899A1 (en) 2017-02-09
EP2604286A1 (en) 2013-06-19
HK1186482A1 (zh) 2014-03-14
EP1625149A4 (en) 2010-10-06
CN101214380A (zh) 2008-07-09
JP4879020B2 (ja) 2012-02-15
ES2520816T3 (es) 2014-11-11
DK2604621T3 (en) 2016-02-01
EP2604621B1 (en) 2015-10-21
EP2604285A1 (en) 2013-06-19
JP2016130246A (ja) 2016-07-21
US20100204448A1 (en) 2010-08-12
JP2007503461A (ja) 2007-02-22
EP1625149A2 (en) 2006-02-15
HK1186406A1 (en) 2014-03-14
PL2604285T3 (pl) 2015-02-27
JP6395749B2 (ja) 2018-09-26
EP3381515B1 (en) 2020-07-08
HK1253888A1 (zh) 2019-07-05
NZ543410A (en) 2008-07-31
DK2604286T3 (en) 2014-12-08
AU2004252419A1 (en) 2005-01-06
JP5995930B2 (ja) 2016-09-21

Similar Documents

Publication Publication Date Title
BRPI0409911A (pt) método para liberar uma molécula em uma célula, e, complexo carreador
BRPI0512396A (pt) polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
BR0016520A (pt) Processo para a redução eletroquìmica de corantes reduzìveis
BRPI0513933A (pt) sistema e método para intercalação de diversidade
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
HRP20090245T1 (en) Pyy agonists and uses thereof
BR9807502B1 (pt) compostos orgÂnicos, processo para sua preparaÇço, bem como composiÇço e aplicaÇço dos mesmos.
WO2000002917A3 (en) Compounds and methods for modulating cadherin-mediated functions
ATE494012T1 (de) Stabilisierte polymer-thiol-reagenzien
IL189595A0 (en) Hydrogel functionalized with a polymerizable moiety and their uses as biosensors or bioreactors
WO2008094945A3 (en) Compounds and methods for modulating protein expression
ATE505549T1 (de) Männliche fertilitätvermittelnde nukleotidsequenzen und deren verwendung
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
WO2008034622A3 (en) A method of detecting and/or quantifying expression of a target protein candidate in a cell, and a method of identifying a target protein of a small molecule modulator
DK1179183T3 (da) Fremgangsmåde til identifikation af præneoplastiske og/eller neoplastiske tilstande hos pattedyr
BRPI0511802A (pt) processo para criação de meios para uso em separadores de ar/óleo
ATE456666T1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
WO2004108749A3 (en) Binding peptides: methods for their generation and use
DE602006010187D1 (de) Einzelsequenzhybridisierungssonden
WO2002083932A3 (de) Enzymabbauketten
NO20025738D0 (no) Metode
BRPI0517904A (pt) uso de polìmeros, e, processo para imprimir por meio da técnica offset
EA200801385A1 (ru) Способ образования дендритных клеток с применением пониженной температуры
BR8201194Y1 (pt) disposição construtiva introduzida em suporte para botijão de gás com sistema para supervisão de consumo à distáncia.
PT1060135E (pt) Processo para controlar as incrustacoes no processamento do acucar.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]